IGF1 and neoplasm: Most patients with stable/controlled disease were characterized by a lack of signs and symptoms (6/9) and a single comorbidity (5/10), a GH nadir following an oral glucose tolerance test (OGTT) of ≤0.4 μg/L (2/2) or GH random/series ≤1 μg/L (7/8), normal IGF-1 levels (9/10), and no tumor (6/10).